Sunil Verma, MD, MSEd, FRCPC takes up the topic of communicating with patients about what they want for their care.
Dr. Steve O’Day discusses the current state of cancer treatments, which focuses less on standard chemotherapy and has begun relying more on targeted therapies and immune-oncology.
PMO is pleased to offer the department “The Biomarker” to discuss the identification of biomarkers in patients with cancer and the prognostic/predictive impact and clinical decision-making implications of that marker. This month, we focus on KIT mutations in melanoma patients. Dr Sanjiv Agarwala provides his insights on this provocative topic.